BioVersys Names Anca Cighi as Head of Investor Relations

BioVersys AG, a Basel-based biopharmaceutical company listed on the SIX Swiss Exchange, has announced the appointment of Anca Cighi as Head of Investor Relations and Communications. The company, focused on developing antibacterial products for drug-resistant infections, values Cighi's experience in corporate communications and capital markets. Her previous roles include Head of Investor Relations & Corporate Affairs at Aramex and Senior Director at FTI Consulting in Dubai.

Hernan Levett, BioVersys CFO, emphasized the importance of transparent communication with investors. Cighi is expected to enhance stakeholder engagement, especially as BioVersys advances its lead asset, BV100, into Phase 3 clinical development and maintains partnerships with GSK and Shionogi.